PAVmed (PAVM) Competitors $0.79 +0.01 (+1.51%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.84 +0.05 (+6.59%) As of 02/21/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PAVM vs. DXR, WOK, POCI, COCH, PYPD, XAIR, SURG, DHAI, IRIX, and NXGLShould you be buying PAVmed stock or one of its competitors? The main competitors of PAVmed include Daxor (DXR), WORK Medical Technology Group LTD Ordinary Shares (WOK), Precision Optics (POCI), Envoy Medical (COCH), PolyPid (PYPD), Beyond Air (XAIR), SurgePays (SURG), DIH Holding US (DHAI), IRIDEX (IRIX), and NEXGEL (NXGL). These companies are all part of the "medical equipment" industry. PAVmed vs. Daxor WORK Medical Technology Group LTD Ordinary Shares Precision Optics Envoy Medical PolyPid Beyond Air SurgePays DIH Holding US IRIDEX NEXGEL PAVmed (NASDAQ:PAVM) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings. Do institutionals and insiders believe in PAVM or DXR? 19.9% of PAVmed shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 11.3% of PAVmed shares are held by insiders. Comparatively, 59.0% of Daxor shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer PAVM or DXR? PAVmed received 202 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 66.12% of users gave PAVmed an outperform vote. CompanyUnderperformOutperformPAVmedOutperform Votes20366.12% Underperform Votes10433.88% DaxorOutperform Votes1100.00% Underperform VotesNo Votes Does the media favor PAVM or DXR? In the previous week, PAVmed and PAVmed both had 3 articles in the media. PAVmed's average media sentiment score of 0.35 beat Daxor's score of 0.00 indicating that PAVmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Daxor 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend PAVM or DXR? PAVmed presently has a consensus target price of $19.00, indicating a potential upside of 2,299.60%. Daxor has a consensus target price of $24.75, indicating a potential upside of 241.85%. Given PAVmed's stronger consensus rating and higher probable upside, equities research analysts clearly believe PAVmed is more favorable than Daxor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, PAVM or DXR? PAVmed has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.46, suggesting that its share price is 146% less volatile than the S&P 500. Is PAVM or DXR more profitable? PAVmed has a net margin of 602.97% compared to Daxor's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets PAVmed602.97% N/A -92.36% Daxor N/A N/A N/A Which has stronger valuation and earnings, PAVM or DXR? Daxor has lower revenue, but higher earnings than PAVmed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPAVmed$2.45M3.58-$64.18M-$4.35-0.18DaxorN/AN/AN/AN/AN/A SummaryPAVmed beats Daxor on 9 of the 12 factors compared between the two stocks. Get PAVmed News Delivered to You Automatically Sign up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PAVM vs. The Competition Export to ExcelMetricPAVmedSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.63M$4.74B$5.84B$9.15BDividend YieldN/A39.90%4.75%3.85%P/E Ratio-0.1828.5326.1519.13Price / Sales3.5853.64435.3370.72Price / CashN/A51.1038.0134.83Price / Book-0.246.577.644.62Net Income-$64.18M$90.91M$3.19B$245.94M7 Day Performance0.23%-2.39%-2.11%-2.62%1 Month Performance34.20%-2.29%-0.49%-2.15%1 Year Performance-57.20%15.21%16.44%12.95% PAVmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PAVMPAVmed4.2877 of 5 stars$0.79+1.5%$19.00+2,299.6%-56.7%$8.63M$2.45M-0.1890News CoverageGap DownDXRDaxor3.4292 of 5 stars$7.18+0.7%$24.75+244.7%-9.5%$34.75MN/A0.0037WOKWORK Medical Technology Group LTD Ordinary SharesN/A$2.28-2.6%N/AN/A$33.06M$9.86M0.00226Lockup ExpirationGap DownPOCIPrecision Optics0.3317 of 5 stars$4.91-1.6%N/A-26.8%$31.18M$19.10M-7.9280News CoverageGap DownCOCHEnvoy Medical2.3906 of 5 stars$1.52+4.8%$8.00+426.3%+13.8%$30.78M$320,000.000.0034Gap UpHigh Trading VolumePYPDPolyPid2.3386 of 5 stars$2.95+4.2%$11.33+284.2%-44.0%$30.06MN/A-0.3880Gap UpXAIRBeyond Air4.6735 of 5 stars$0.39+4.7%$3.67+842.6%-81.0%$29.58M$1.16M-0.2870SURGSurgePays2.8497 of 5 stars$1.46-2.0%$8.50+482.2%-80.7%$29.43M$137.14M-1.2940DHAIDIH Holding USN/A$0.65+1.1%N/A-59.4%$26.15M$64.47M0.00N/AEarnings ReportGap UpIRIXIRIDEX0.962 of 5 stars$1.55+2.6%$2.00+29.0%-38.6%$25.79M$51.87M-2.31120Analyst ForecastNews CoverageGap UpNXGLNEXGELN/A$3.53+4.7%N/A+68.5%$23.97M$6.73M-6.0910Gap Down Related Companies and Tools Related Companies Daxor Competitors WORK Medical Technology Group LTD Ordinary Shares Competitors Precision Optics Competitors Envoy Medical Competitors PolyPid Competitors Beyond Air Competitors SurgePays Competitors DIH Holding US Competitors IRIDEX Competitors NEXGEL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PAVM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
